APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

Summary

APOLLO 11 main aim is to build a strong Italian long-lasting lung cancer network (in around 48 Italian centres) on real world data and translational research by creating a decentralized long-term national database (settle locally in each centre) and a "virtual" multilevel biobank in each centre. Besides, APOLLO 11 will take advantage of the translational research joint effort with the credo "unity is strength".

Eligibility

Inclusion Criteria:

1. Provision of signed and dated written informed consent, when applicable, by the patient or legally acceptable representative prior to any mandatory study-specific procedures, sampling, and analyses;
2. Patients must be ≥18 years of age at the time of signing the informed consent;
3. Histologically or cytologically confirmed lung cancer (NSCLC or SCLC) at any stage (I-IV) candidate to receive or already treated with innovative therapies (ICIs, target therapies and next generation therapies).

Exclusion Criteria:

1. Patients who are or will be taking other unapproved antineoplastic therapies concurrently are not eligible.
2. Patients who have not received an oncological systemic innovative therapy at any setting
3. Patients received only local treatments (e.g., only surgery, or only radiotherapy)
4. Patients who received only standard chemotherapy are excluded.
5. Patients who received treatment therapies before 2010 are excluded.

Conditions5

Browse More Trials